NCT00286793 2011-06-29
Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC
Ascenta Therapeutics
Phase 1/2 Completed
Clinical Trials
3 trialsNCT00571675 2010-11-09
A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)
Ascenta Therapeutics
Phase 2 Completed
NCT00286806 2010-08-24
A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer
Ascenta Therapeutics
Phase 1/2 Completed